 |
SAN JOSE, Calif., Feb. 14, 2018 /PRNewswire/ -- Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its fourth quarter and full year ended December 31, 2017.
Results Highlights:
"The fourth quarter of 2017 marked Intermolecular's first GAAP profitable quarter in five years, driven by a 22% increase in revenue and a 10% decrease in operating expense as compared to the prior quarter," said company president and CEO, Chris Kramer. "From an operational standpoint, we added three new programs during the fourth quarter and we also formed an important strategic alliance with the Shanghai Industrial Technology Research Institute (SITRI), which we believe will drive future revenue opportunities for Intermolecular in the second half of 2018 and beyond."
Fourth Quarter Fiscal 2017 Results
Revenue for the fourth quarter of 2017 was $10.5 million, up 22% compared to $8.6 million in the third quarter of 2017, and up 1% compared to $10.5 million in the same period a year ago.
Net income for the fourth quarter of 2017 was $0.1 million, or $0.00 per share, compared to net loss of $(1.8) million, or $(0.04) per share, in the third quarter of 2017 and net loss of $(3.0) million, or $(0.06) per share, in the same period a year ago.
Non-GAAP net income for the fourth quarter of 2017 was $0.4 million, or $0.01 per share, compared to non-GAAP net loss of $(1.6) million, or $(0.03) per share, in the prior quarter and non-GAAP net loss of $(2.3) million, or $(0.05) per share, in the same period a year ago.
Adjusted EBITDA for the fourth quarter of 2017 was $2.1 million, compared to $0.1 million in the prior quarter and Adjusted EBITDA loss of $(0.5) million in the same period a year ago.
Cash and investments were $25.8 million at the end of fourth quarter of 2017, a decrease of $1.3 million compared to $27.1 million at the end of third quarter of 2017.
Full Year Fiscal 2017 Results
Revenue for the full year ended December 31, 2017 was $37.2 million, down 21% compared to $47.3 million in 2016. The decrease in revenue was primarily due to the strategic transition of the company's business model in 2017 from a royalty and services model to a services-based program model.
Net loss for the full year ended December 31, 2017 was $(10.4) million, or $(0.21) per share, compared with $(15.4) million, or $(0.31) per share, for 2016.
Non-GAAP net loss for 2017 was $(8.9) million, or $(0.18) per share, compared to $(11.8) million, or $(0.24) per share, for 2016.
Cash and investments were $25.8 million at the end of 2017, compared to $27.8 million at the end of 2016.
First Quarter of 2018 Outlook
The following statements are based on Intermolecular's current expectations for the first quarter ending March 31, 2018. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below. Intermolecular does not plan to update, nor does it undertake any obligation to update, this outlook in the future.
Intermolecular reports revenue, cost of revenue, gross margin, operating income (loss), net income (loss) and earnings (loss) per share in accordance with U.S. generally accepted accounting principles (GAAP) and additionally on a non-GAAP basis. A reconciliation of the non-GAAP financial measures with the most directly comparable GAAP measures, as well as a description of the items excluded from the non-GAAP measures, is included in the financial statements portion of this press release. Please refer to "Reconciliation of GAAP to Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Loss to Non-GAAP Net Loss" below.
Conference Call
Intermolecular will host a conference call and simultaneous audio-only webcast today (February 13, 2018) at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss these results. The call will be hosted by Intermolecular President and CEO Chris Kramer and CFO Bill Roeschlein.
U.S. dial-in number: (877) 251-1860
International dial-in number: (244) 357-2386
Conference ID: 5955988
Please call the conference telephone number five to ten minutes prior to start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact Liolios Group at (949) 574-2386
A live and archived webcast (audio only) of the call will be available on Intermolecular's website for up to 30 days after the call.
About Intermolecular, Inc.
Intermolecular® is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation in the 21st century for a wide range of industries including semiconductors, consumer electronics, automotive and aerospace. With its substantial materials expertise; accelerated learning and experimentation platform; and information and analytics infrastructure, Intermolecular has a ten-year track record helping leading companies accelerate and de-risk materials innovation.
"Intermolecular" and the Intermolecular logo are registered trademarks; all rights reserved. Learn more at www.intermolecular.com.
Forward-Looking Statements
Statements made in this press release and the earnings call referencing the press release that are not statements of historical fact are forward-looking statements. Forward-looking statements are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "expects," "believes," "plans," "intends," "projects" and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this document are based on current beliefs, assumptions and expectations, speak only as of the date of this document and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and generally beyond Intermolecular's control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: our ability to productize our workflows with existing and future customers; expectations regarding our future revenue, cash flow and GAAP and non-GAAP net income or loss; financial condition; the ability of our new business model to generate profits and long-term shareholder returns; the extent to which technology developed in collaboration with our customers will continue to remain on the critical path and have significant value for such customers and us as well as the industry as a whole; and anticipated growth in our current markets through expansion of existing customer programs and the entry into other engagements with new customers. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: our ability to execute on our strategy, prove our business model and remain technologically competitive in rapidly evolving industry conditions; commercial acceptance of our HPC platform and methodology as effective R&D tools; our ability to achieve and sustain profitability; the ability of our customers to achieve their announced product roadmaps in a timely manner; the extent to which we are able to successfully extend and expand relationships with existing customers; our ability to manage the growth of our business; the rapid technology changes and volatility of the customers and industries we serve; our potential need for future capital to finance our operations; and other risks described in our most recent annual report on Form 10-K as updated by our quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission available at www.sec.gov, particularly in the sections titled "Risk Factors." All forward-looking statements are based on management's current estimates, projections and assumptions, and we assume no obligation to update them.
Non-GAAP Financial Measures
To supplement the financial data presented on a GAAP basis, we also disclose certain non-GAAP financial measures, which exclude the effect of stock-based compensation expense. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than non-GAAP financial information disclosed by other companies. These results should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. We believe that our non-GAAP financial information provides useful information to management and investors regarding financial and business trends relating to our financial condition and results of operations because the non-GAAP measures exclude charges that management considers to be outside of Intermolecular's core operating results. We believe that the non-GAAP measures of revenue, cost of net revenue, gross profit, gross margin, operating (loss) income, net (loss) income, earnings per share and net (loss) income per share, viewed in combination with our financial results calculated in accordance with GAAP, provide investors with additional perspective and a more meaningful understanding of our ongoing operating performance. In addition, management uses these non-GAAP measures to review and assess financial performance, to determine executive officer incentive compensation and to plan and forecast performance in future periods.
| Intermolecular, Inc. |
|||||||||||
| Condensed Consolidated Statements of Operations |
|||||||||||
| (In thousands, except per share amounts, Unaudited) |
|||||||||||
| Three Months Ended |
Twelve Months Ended |
||||||||||
| 2017 |
2016 |
2017 |
2016 |
||||||||
| Revenue: |
|||||||||||
| Program revenue |
$ |
8,850 |
$ |
8,833 |
$ |
29,010 |
$ |
39,690 |
|||
| Licensing and royalty revenue |
1,698 |
1,644 |
8,193 |
7,608 |
|||||||
| Total revenue |
10,548 |
10,477 |
37,203 |
47,298 |
|||||||
| Cost of revenue: |
|||||||||||
| Cost of program revenue |
3,353 |
3,421 |
11,449 |
15,705 |
|||||||
| Cost of licensing and royalty revenue |
344 |
25 |
656 |
125 |
|||||||
| Total cost of revenue |
3,697 |
3,446 |
12,105 |
15,830 |
|||||||
| Gross profit |
6,851 |
7,031 |
25,098 |
31,468 |
|||||||
| Operating expenses: |
|||||||||||
| Research and development |
4,206 |
5,847 |
21,535 |
28,126 |
|||||||
| Sales and marketing |
734 |
1,518 |
4,019 |
7,383 |
|||||||
| General and administrative |
1,974 |
2,777 |
9,198 |
10,713 |
|||||||
| Restructuring charges |
— |
(6) |
1,351 |
1,114 |
|||||||
| Total operating expenses |
6,914 |
10,136 |
36,103 |
47,336 |
|||||||
| Loss from operations |
(63) |
(3,105) |
(11,005) |
(15,868) |
|||||||
| Other income (expense): |
|||||||||||
| Interest income (expense), net |
84 |
50 |
266 |
173 |
|||||||
| Other income (expense), net |
95 |
63 |
337 |
265 |
|||||||
| Total other income (expense), net |
179 |
113 |
603 |
438 |
|||||||
| Income (loss) before provision for income taxes |
116 |
(2,992) |
(10,402) |
(15,430) |
|||||||
| Provision for income taxes |
- |
- |
1 |
7 |
|||||||
| Net income (loss) |
$ |
116 |
$ |
(2,992) |
$ |
(10,403) |
$ |
(15,437) |
|||
| Basic net income (loss) per common share |
$ |
0.00 |
$ |
(0.06) |
$ |
(0.21) |
$ |
(0.31) |
|||
| Diluted net income (loss) per common share |
$ |
0.00 |
$ |
(0.06) |
$ |
(0.21) |
$ |
(0.31) |
|||
| Shares used in basic net income (loss) per common share |
49,559 |
49,486 |
49,547 |
49,396 |
|||||||
| Shares used in diluted net income (loss) per common share |
49,765 |
49,486 |
49,547 |
49,396 |
|||||||
| Intermolecular, Inc. |
|||||
| Condensed Consolidated Balance Sheets |
|||||
| (In thousands, Unaudited) |
|||||
| As of December 31, |
As of December 31, |
||||
| ASSETS |
|||||
| Current assets: |
|||||
| Cash and cash equivalents |
$ |
6,090 |
$ |
5,759 |
|
| Short-term investments |
18,060 |
20,035 |
|||
| Total cash, cash equivalents and short-term investments |
24,150 |
25,794 |
|||
| Accounts receivable |
5,519 |
5,063 |
|||
| Prepaid expenses and other current assets |
1,069 |
1,397 |
|||
| Total current assets |
30,738 |
32,254 |
|||
| Long-term investments |
1,657 |
1,995 |
|||
| Materials inventory |
2,781 |
3,357 |
|||
| Property and equipment, net |
5,913 |
10,964 |
|||
| Intangible assets, net |
2,620 |
4,001 |
|||
| Other assets |
600 |
597 |
|||
| Total assets |
$ |
44,309 |
$ |
53,168 |
|
| LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||
| Current liabilities: |
|||||
| Accounts payable |
$ |
928 |
$ |
309 |
|
| Accrued liabilities |
865 |
1,451 |
|||
| Accrued compensation and employee benefits |
2,535 |
1,663 |
|||
| Deferred revenue |
941 |
1,533 |
|||
| Total current liabilities |
5,269 |
4,956 |
|||
| Other long-term liabilities |
2,967 |
3,216 |
|||
| Total liabilities |
8,236 |
8,172 |
|||
| Stockholders' equity: |
|||||
| Common stock |
50 |
50 |
|||
| Additional paid-in capital |
214,796 |
213,313 |
|||
| Accumulated other comprehensive loss |
(36) |
(32) |
|||
| Accumulated deficit |
(178,737) |
(168,335) |
|||
| Total stockholders' equity |
36,073 |
44,996 |
|||
| Total liabilities and stockholders' equity |
$ |
44,309 |
$ |
53,168 |
|
| Intermolecular, Inc. |
|||||
| Condensed Consolidated Statements of Cash Flows |
|||||
| (In thousands, Unaudited) |
|||||
| Twelve Months Ended December 31, |
|||||
| 2017 |
2016 |
||||
| Cash flows from operating activities: |
|||||
| Net loss |
$ |
(10,403) |
$ |
(15,437) |
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|||||
| Depreciation, amortization and accretion |
7,194 |
9,537 |
|||
| Stock-based compensation |
1,472 |
3,627 |
|||
| (Gain) loss on disposal of property and equipment |
68 |
(12) |
|||
| Changes in operating assets and liabilities: |
|||||
| Accounts receivable |
(456) |
1,051 |
|||
| Prepaid expenses and other assets |
585 |
122 |
|||
| Materials inventory |
557 |
333 |
|||
| Accounts payable |
592 |
(493) |
|||
| Accrued and other liabilities |
110 |
(3,069) |
|||
| Deferred revenue |
(592) |
(1,063) |
|||
| Net cash used in operating activities |
(873) |
(5,404) |
|||
| Cash flows from investing activities: |
|||||
| Purchase of investments |
(20,888) |
(23,486) |
|||
| Redemption of investments |
22,861 |
24,676 |
|||
| Purchase of property and equipment |
(777) |
(2,381) |
|||
| Proceeds from sale of equipment |
14 |
22 |
|||
| Purchased and capitalized intangible assets |
— |
(45) |
|||
| Net cash (used in) provided by investing activities |
1,210 |
(1,214) |
|||
| Cash flows from financing activities: |
|||||
| Payment of capital leases |
(13) |
(13) |
|||
| Proceeds from exercise of common stock options |
7 |
714 |
|||
| Net cash (used in) provided by financing activities |
(6) |
701 |
|||
| Net increase (decrease) in cash and cash equivalents |
331 |
(5,917) |
|||
| Cash and cash equivalents at beginning of period |
5,759 |
11,676 |
|||
| Cash and cash equivalents at end of period |
$ |
6,090 |
$ |
5,759 |
|
| Intermolecular, Inc. |
|||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||||||||||
| (In thousands, except per share amounts and percentages, Unaudited) |
|||||||||||||||
| Three Months Ended |
Twelve Months Ended |
||||||||||||||
| 2017 |
2016 |
2017 |
2016 |
||||||||||||
| GAAP cost of net revenue |
$ |
3,697 |
$ |
3,446 |
$ |
12,105 |
$ |
15,830 |
|||||||
| Stock-based compensation expense (a) |
(47) |
(102) |
(191) |
(510) |
|||||||||||
| Non-GAAP cost of net revenue |
$ |
3,650 |
$ |
3,344 |
$ |
11,914 |
$ |
15,320 |
|||||||
| GAAP gross profit |
$ |
6,851 |
$ |
7,031 |
$ |
25,098 |
$ |
31,468 |
|||||||
| Stock-based compensation expense (a) |
47 |
102 |
191 |
510 |
|||||||||||
| Non-GAAP gross profit |
$ |
6,898 |
$ |
7,133 |
$ |
25,289 |
$ |
31,978 |
|||||||
| As a percentage of net revenue: |
|||||||||||||||
| GAAP gross margin |
65.0 |
% |
67.1 |
% |
67.5 |
% |
66.5 |
% |
|||||||
| Non-GAAP gross margin |
65.4 |
% |
68.1 |
% |
68.0 |
% |
67.6 |
% |
|||||||
| GAAP operating loss |
$ |
(63) |
$ |
(3,105) |
$ |
(11,005) |
$ |
(15,868) |
|||||||
| Stock-based compensation expense (a): |
|||||||||||||||
| - Cost of net revenue |
47 |
102 |
191 |
510 |
|||||||||||
| - Research and development |
66 |
189 |
373 |
949 |
|||||||||||
| - Sales and marketing |
23 |
(40) |
119 |
527 |
|||||||||||
| - General and administrative |
115 |
440 |
789 |
1,641 |
|||||||||||
| Non-GAAP operating income (loss) |
$ |
188 |
$ |
(2,414) |
$ |
(9,533) |
$ |
(12,241) |
|||||||
| GAAP net income (loss) |
$ |
116 |
$ |
(2,992) |
$ |
(10,403) |
$ |
(15,437) |
|||||||
| Stock-based compensation expense (a) |
251 |
691 |
1,472 |
3,627 |
|||||||||||
| Non-GAAP net income (loss) |
$ |
367 |
$ |
(2,301) |
$ |
(8,931) |
$ |
(11,810) |
|||||||
| GAAP net income (loss) |
$ |
116 |
$ |
(2,992) |
$ |
(10,403) |
$ |
(15,437) |
|||||||
| Interest (income) expense, net |
(84) |
(50) |
(266) |
(173) |
|||||||||||
| Provision for taxes |
— |
— |
1 |
7 |
|||||||||||
| Depreciation, amortization, impairment and accretion |
1,824 |
1,829 |
7,194 |
9,537 |
|||||||||||
| Restructuring charges (b) |
— |
(6) |
1,351 |
1,114 |
|||||||||||
| Stock based compensation expense (a) |
251 |
691 |
1,472 |
3,627 |
|||||||||||
| Adjusted EBITDA |
$ |
2,107 |
$ |
(528) |
$ |
(651) |
$ |
(1,325) |
|||||||
| Shares used in computing earnings per share: |
|||||||||||||||
| Basic |
49,559 |
49,486 |
49,547 |
49,396 |
|||||||||||
| Diluted |
49,765 |
49,486 |
49,547 |
49,396 |
|||||||||||
| GAAP earnings (loss) per share: |
|||||||||||||||
| Basic |
$ |
0.00 |
$ |
(0.06) |
$ |
(0.21) |
$ |
(0.31) |
|||||||
| Diluted |
$ |
0.00 |
$ |
(0.06) |
$ |
(0.21) |
$ |
(0.31) |
|||||||
| Non-GAAP earnings (loss) per share: |
|||||||||||||||
| Basic |
$ |
0.01 |
$ |
(0.05) |
$ |
(0.18) |
$ |
(0.24) |
|||||||
| Diluted |
$ |
0.01 |
$ |
(0.05) |
$ |
(0.18) |
$ |
(0.24) |
|||||||
| (a) |
Stock-based compensation reflects expense recorded relating to stock-based awards. The Company excludes this item when it evaluates the continuing operational performance of the Company, as management believes this provides it a meaningful understanding of its core operating performance. |
| (b) |
Restructuring charges incurred in connection with a reduction in headcount primarily comprised of employee severance and benefit costs. |
| Intermolecular, Inc. |
|||||
| First Quarter 2018 Outlook |
|||||
| Reconciliation of GAAP Net Loss to Non-GAAP Net Loss |
|||||
| (In thousands, except per share amounts, Unaudited) |
|||||
| GAAP net loss range |
$(1,000) |
- |
$(1,300) |
||
| Stock-based compensation |
$300 |
- |
$300 |
||
| Non-GAAP net loss range |
$(700) |
- |
$(1,000) |
||
| GAAP and Non-GAAP diluted shares |
49,600 |
||||
| GAAP net loss per share range |
$(0.02) |
- |
$(0.03) |
||
| Non-GAAP net loss per share range |
$(0.01) |
- |
$(0.02) |
||
Corporate Contact:
Bill Roeschlein
Intermolecular, Inc.
Chief Financial Officer
bill.roeschlein@intermolecular.com
(408) 582-5415
Investor Contact:
Matt Glover or Najim Mostamand, CFA
Liolios Group, Inc.
IMI@liolios.com
(949) 574-3860
